anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Ventricular bigeminy due to myocardial ischemia has been reported in humans as well as in canine patients with obstructive gastrointestinal diseases. This is the first case report of ventricular bigeminy in a dog with a colonic torsion that resolved after fluid resuscitation and restoration of myocardial perfusion.
CASE PRESENTATION: An 11-year-old, male neutered mixed breed dog presented with a one day history of vomiting, tenesmus, and lethargy. Physical examination identified an irregular heart rhythm and intermittent pulse deficits. A ventricular arrhythmia represented by ventricular premature complexes (VPCs) organized in bigeminy, was appreciated on a 3-lead electrocardiogram (ECG) with a single lead (II) view. Abdominal radiographs confirmed a colonic torsion. Prior to anesthetic induction, ventricular bigeminy was non responsive to fentanyl or lidocaine. The patient was anesthetized and intravascular volume deficit was identified by dampened plethysmographic wave amplitude (plethysomographic variability), audible softening of the Doppler sound, and more pronounced pulse deficits. Fluid resuscitation was achieved with a combination of intravenous crystalloid and colloid fluid therapy comprising 7.2% hypertonic saline and 6% hetastarch. The patient's cardiac rhythm converted to normal sinus after fluid resuscitation. The colonic torsion was surgically corrected. The patient recovered well from anesthesia and was ultimately discharged from the hospital 5 days later.
CONCLUSIONS: The present case report highlights that myocardial ischemia can lead to ventricular arrythmias, such as ventricular bigeminy. This is the first documented case of ventricular bigeminy in the canine patient with a colonic torsion. Assessment of patient volume status and appropriate fluid resuscitation along with continuous electrocardiogram (ECG) monitoring are vital to patient stability under general anesthesia.
44 apically infected periapical lesions were decided to enroll to the study from December 2016-November 2017. However; a total of 40 periapical lesions undergoing apical surgery were recruited for the planned clinical trial in the end. The study was conducted under randomized controlled protocol. Patients were informed about the surgical procedures and signed a consent form. The anticipated outcomes, possible risks and benefits of the study as well as the alternative treatment options were explained to the patients.

Groups were designed to have 10 patients in each and randomly divided into four as; control, MTA, PRF and MTA+PRF. Apical resection was performed in all groups. No other interventions were made to the control group.

Routine radiographs were taken in the 1st. 3th and 6th months. In the 12th month of the procedures computerized tomography (CT) scans were taken. Primary healing of the periapical tissues were evaluated according to the volumes and the densities of the lesions. Outcomes were measured. Comparison between the initial and the last 3D CT scan volumes were made by medical image processing software (MIMICS, Belgium). Patients have still been under control for the long term outcomes of the study.
Body As A Whole: Allergic Reaction. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). 

Gastrointestinal System: Gastrointestinal symptoms occur frequently and include anorexia, vague gastric upset, nausea and vomiting, cramps, epigastric and abdominal pain, weight loss, and diarrhea. There have been reports of gum hypertrophy and swelling of the tongue.

Hemopoietic System: Hemopoietic complications associated with the administration of ethosuximide have included leukopenia, agranulocytosis, pancytopenia, with or without bone marrow suppression, and eosinophilia, and thrombocytopenia (See WARNINGS).

Nervous System: Neurologic and sensory reactions reported during therapy with ethosuximide have included drowsiness, headache, dizziness, euphoria, hiccups, irritability, hyperactivity, lethargy, fatigue, and ataxia. Psychiatric or psychological aberrations associated with ethosuximide administration have included disturbances of sleep, night terrors, inability to concentrate, and aggressiveness. These effects may be noted particularly in patients who have previously exhibited psychological abnormalities. There have been rare reports of paranoid psychosis, increased libido, and increased state of depression with overt suicidal intentions.

Integumentary System: Dermatologic manifestations which have occurred with the administration of ethosuximide have included urticaria, pruritic erythematous rashes, Stevens-Johnson syndrome, and hirsutism.

Special Senses: Myopia.

Genitourinary System: Vaginal bleeding, microscopic hematuria.
An injection for needleless injection, in the form of powder, comprises a biological product and an inorganic salt with water of crystallization removed, a mass ratio of the biological product to the inorganic salt being 1:20 to 1:80. The powder is solid particles formed of the biological product wrapped by an external surface of the inorganic salt with water of crystallization removed. The particle diameter of the powder is 20 to 200 micrometers, and preferably, 50 to 70 micrometers. The injection of the present invention may also comprise a tackifier or a Chinese medicinal adjuvant. The mass ratio of the biological product to the tackifier or Chinese medicinal adjuvant to the inorganic salt with water of crystallization removed is 1:0.2:20 to 1:10:80. Also disclosed are a preparation method of the injection for needleless injection, applications of the injection in preparing medicine for preventing or curing diseases, and a method for performing needleless injection by using the injection.
<P>PROBLEM TO BE SOLVED: To provide a humectant for skin and a skin care preparation, capable of readily and remarkably enhancing a skin moisturizing effect.  <P>SOLUTION: The skin moisturizing agent contains a red wine yeast extract as an effective ingredient, and further contains first and second ingredients as effective ingredients. The skin care preparation contains a red wine yeast extract as an effective ingredient, and further contains first and second ingredients as effective ingredients. The first ingredient is at least one selected from a Prunus spp. extract, a carrot extract, a rose extract, a Rubus Ellipiticus Root Extract, an Equisetum arvense extract, a Perilla frutescens seed extract and a grape seed extract. The second ingredient is at least one of hydrolyzed algin and a Perilla frutescens extract.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE:To make it possible to extract industrially eisenin, by dipping a dried edible seaweed (Eisenia bicyclis) in purified water, treating the resultant leachate with a basic lead acetate powder and mercuric acetate powder, adjusting the pH, filtering the resultant white precipitates. CONSTITUTION:A dried edible seaweed (Eisenia bicyclis) is dipped in purified water for a given time to leach a proteinic substance, and the resultant leachate is then acidified with hydrochloric acid, heated and filtered. A soluton of caustic soda is then added to neutralize the filtrate, and basic lead acetate powder is then added to form precipitates, which are filtered to give a colorless transparent filtrate. A necessary amount of mercuric acetate is added to the resultant filtrate, and the pH is adjusted to 6.0 with caustic soda and form white precipitates, which are then filtered, washed with water and subjected to the removal of mercury with hydrogen sulfide while floated on water. The resultant filtrate is concentrated under reduced pressure to solidify the contents, which are shaken with methanol. The resultant crystalline precipitates are then recrystallized from methanol to give the aimed eisenin.
The present disclosure relates to a composition comprising cannabis extracts and methods of manufacturing same. The composition comprises a powder that is formed from vapour or oil that has been extracted from a cannabis plant. The oil may be mixed with a thickener to form the powder. Alternatively, the vapour may be extracted from the cannabis plant and collected in a filter medium, which is then dehydrated and ground into a powder. The vapour may be extracted in a chamber at high temperature, and may then be condensed after extraction in a chamber at low temperature, which may also be a vacuum chamber. The dehydration of the filter medium may take place under a UV light in a chamber kept at about 60 C. The potency of the product may be tested at various intermediate steps in the manufacturing process. The composition is preferably in the form of a pill.
A process for the production of benzoic acid-4-sulphonamides comprises reacting a benzoic acid-4-sulphohalide substituted in the 2-position of the phenyl radical by a methyl group, a chlorine atom or a group which can be replaced by a chlorine atom, with a mono- or di-alkylamine, piperidine or a C-alkyl piperidine or an aralkylamine, said amine having a total of not less than 5 and not more than 8 carbon atoms and, in the case where the substituent in the 2-position of the phenyl radical is a group which can be replaced by a chlorine atom, replacing said group by a chlorine atom.  A modification of the process comprises the use as a starting material of a derivative of a benzoic-acid-4-sulphohalide wherein the carboxy group is replaced by a group convertible thereto, such as cyano, carbonamide and carboxylic acid ester, and this group is converted into the carboxyl group in the sulphonamide which is obtained.  The reaction may be carried out in an aqueous or organic solvent medium, preferably in the presence of acid-fixing agents such as alkali metal hydroxides or carbonates or organic bases, e.g. pyridine.  Specified amines are di-n-butylamine, di-n-propylamine, di-isopropylamine, ethyl-butamine, piperidine, C-alkyl piperidines, n-hexylamine and benzylamine.  In examples: (1) 2 - chlorobenzoic acid - 4 - sulphochloride was reacted with di-n-propylamine, di-n-butylamine, di-isopropylamine, benzylamine and piperidine to give 2-chlorobenzoic acid-4-sulphonic acid-di-n-propylamide, -di-n-butylamide, -di-isopropylamide, -benzylamide and -piperidide; (2) 2-methyl-benzonitrile-4-sulphochloride was reacted with di-n-propylamine to give 2-methyl-benzonitrile-4-sulphonic acid di-n-propylamide which was hydrolysed with alcoholic caustic potash to 2-methyl-benzoic acid-4-sulphonic acid-di-n-propylamide; (3) di-n-propylamine was reacted with 2-nitro-benzoic acid-4-sulphochloride to give 2-nitrobenzoic acid-4-sulphonic acid-di-n-propylamide which was reduced with iron and acetic acid to 2-aminobenzoic acid-4-sulphonic acid-di-n-propylamide which was diazotized and reacted with cuprous chloride and hydrochloric acid to give 2-chlorobenzoic acid-4-sulphonic acid-di-n-propylamide. 2-Chlorobenzoic acid-4-sulphochloride was prepared by treating 2-chlorobenzoic acid-4-sulphonic acid with chlorosulphonic acid.
The present invention relates to a gel composition for cleansing with excellent effects of pore tightening and skin elasticity and a producing method thereof. More specifically, when being discharged in an aerosol form, gas collected in a gel matrix has a vision effect as the gas pops and bubbles up, and pores are tightened and the skin elasticity is improved by an astringent function through lowered skin temperature generated from the evaporation heat. Simultaneously, the gel composition makes easy mixture with matters to be cleansed on the skin hence the cleansing effect is enhanced. Especially, it is not a pleasant experience to remove a heavy make up in summer. In this case, spraying the cleansing cosmetic material of the aerosol type to remove make up through the evaporation heat does not only provide a refreshing feeling but also substantially cools down the skin temperature. Thus, the present invention can be regarded as an epoch-making effect in terms of cosmetic items.
A device and method for strengthening a natural fingernail includes a nail reinforcing device made of a pliable and conformable material having a thickness that is less than the thickness of a natural fingernail. The nail reinforcing device can be preformed and shaped to correspond to the shape of a natural fingernail or can be shaped to correspond to the general shape of the natural fingernail to which it is attached or adhered. A method for strengthening a natural fingernail of the present invention comprises applying an adhesive to at least a portion of the bottom (underneath) surface of the free end of the natural fingernail, to at least a portion of the top surface of the natural fingernail, or to at least a portion of the upper surface of the nail reinforcing device. The body of the nail reinforcing device is then positioned and maintained under the natural fingernail so as to provide contact between the upper surface of the nail reinforcing device and the bottom surface of the natural fingernail. The sides of the nail reinforcing device are then folded so as to place the upper surface of the nail reinforcing device in contact with the top surface of the natural fingernail. The sides of the nail reinforcing device may be shaped to form decorative patterns on the top surface of the natural fingernail. The method and device can also be used for reattaching a broken fingernail by attaching or adhering the nail reinforcing device to the bottom surface of the detached and remaining portions of the broken fingernail. The method and device can also be used to repair a damaged fingernail. Once the nail reinforcing device has been attached or adhered to the natural fingernail, a filler material is applied to a portion of the nail reinforcing device underlying a damaged portion of the fingernail.
Administer alprazolam extended-release tablets orally once daily, preferably in the morning. Swallow tablets whole; do not divide, crush, or chew.

The recommended starting oral dosage for alprazolam extended-release tablets is 0.5 mg to 1 mg once daily. Depending on the response, the dosage may be adjusted at intervals of every 3 to 4 days in increments of no more than 1 mg daily. The recommended dosage range is 3 mg to 6 mg once daily.  


Controlled trials of alprazolam extended-release tablets for the treatment of panic disorder included dosages in the range of 1 mg to 10 mg per day. Most patients showed a response in the dosage range of 3 mg to 6 mg per day. Occasional patients required as much as 10 mg per day.  


The longer-term efficacy of alprazolam extended-release tablets has not been systematically evaluated. If alprazolam extended-release tablets is used for periods longer than 8 weeks, the healthcare provider should periodically reassess the usefulness of the drug for the individual patient.  


After a period of extended freedom from panic attacks, a carefully supervised tapered discontinuation may be attempted, but there is evidence that this may often be difficult to accomplish without recurrence of symptoms and/or the manifestation of withdrawal phenomena [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].
In this study, we aimed to explore the risk factors influencing post-recurrence survival (PRS) of early recurrence (ER) and late recurrence (LR) in stage advanced gastric cancer (AGC) patients after radical surgery, respectively, and to develop predictive models in turn. Medical records of 192 AGC patients who recurred after radical gastrectomy were retrospectively reviewed. They were randomly divided into the training and validation set at a ratio of 2:1. Nomograms were built based on risk factors influencing PRS of ER and LR explored by Cox regression analyses, respectively. Concordance index (C-index) values and calibration curves were used to evaluate predictive power of nomograms. Body mass index < 18.5 kg/m2, prealbumin level < 70.1 mg/L, positive lymph nodes ratio ≥ 0.486 and palliative treatment after recurrence were independent risk factors for the prognosis of ER. In contrast, prealbumin level < 170.1 mg/L, CEA ≥ 18.32 μg/L, tumor diameter ≥ 5.5 cm and palliative treatment after recurrence were independent risk factors for the prognosis of LR. The C-index values were 0.801 and 0.772 for ER and LR in the training set, respectively. The calibration curves of validation set showed a C-index value of 0.744 and 0.676 for ER and LR, respectively. Nomograms which were constructed to predict the prognosis of ER and LR of AGC after surgery showed great predictive power and could provide reference for clinicians' treatment strategies to some extent.
Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
PURPOSE: To assess the risk of adverse obstetric and perinatal outcomes in subsequent pregnancies among women with a history of recurrent pregnancy loss (RPL).
METHODS: Relevant studies were identified by searching the PubMed, Web of Science, and Embase databases. The pooled effect sizes were reported as odds ratios (OR) with their respective 95% confidence intervals (95% CI), and data analysis was performed using the random effects model.
RESULTS: A total of 26 studies involving 4,730,728 women were included in this meta-analysis. The results reveal a significant increase in the prevalence of placenta accreta cases after RPL compared to women without RPL (pooled OR 4.04; 95% CI 1.16-14.15; 2 studies; I2 = 94%; P = 0.03). However, no elevated risk of aneuploidies (pooled OR 1.69, 95% CI 0.73-3.90; 5 studies; I2 = 48%; P = 0.22) or congenital anomalies (pooled OR 1.12, 95% CI 0.97-1.30; 7 studies; I2 = 13%; P = 0.12) in subsequent pregnancies of women with RPL was observed. Additionally, a moderate increase in the risk of various other obstetric and perinatal outcomes was found. The magnitude of the elevated risk of these adverse outcomes varied depending on the region.
CONCLUSIONS: Women with a history of RPL exhibit a significantly elevated risk of placenta accreta in subsequent pregnancies, along with a moderate increase in the risk of various other adverse obstetric and perinatal outcomes. However, RPL does not signify an increased risk of aneuploidies or congenital anomalies in a consecutive pregnancy.
This study examined the effects of time restricted eating (TRE) on sex hormones in males and females, versus daily calorie restriction (CR). Adults with obesity (n = 90) were randomized to 1 of 3 groups for 12-months: 8-h TRE (eating only between 12:00 to 8:00 pm, with no calorie counting); CR (25% energy restriction daily); or control. Body weight decreased (P < 0.01) in the TRE and CR groups, relative to controls, in males, premenopausal females, and postmenopausal females, by month 12. Total testosterone, dehydroepiandrosterone (DHEA), and sex hormone binding globulin (SHBG) levels did not change over time, or between groups, in males, premenopausal females, and postmenopausal females. Estradiol, estrone, and progesterone were only measured in postmenopausal females, and remained unchanged. These findings suggest that TRE produces significant weight loss but does not impact circulating sex hormone levels in males and females with obesity over 12 months, relative to CR and controls.
Adopting disease-tolerant grapevines is an efficient option to implement a smarter management strategy limiting the environmental impacts linked to pesticide use. However, little is known on their production of fruit metabolites regarding expected future climate fluctuations, such as increased water shortage. Moreover, previous studies about how water deficit impacts grape composition, lack accuracy due to imprecise timing of fruit sampling. In this study, we phenotyped six new fungus-tolerant genotypes exposed to varying water status in field-grown conditions. The accumulation of water, main cations, primary and secondary metabolites were precisely monitored at the arrest of phloem unloading in fruits, which was targeted at the whole cluster level. The goal was to decipher the effects of both genotype and water deficit on the allocation of carbon into soluble sugars, organic acids, amino acids and anthocyanins. The results revealed that the effect of decreased water availability was specific to each berry component. While fruit sugar concentration remained relatively unaffected, the malic/tartaric acid balance varied based on differences among genotypes. Despite showing contrasted strategies on carbon allocation into berry metabolites, all genotypes reduced fruit yield and the amount of compounds of interest per plant under water deficit, with the extent of reduction being genotype-dependent and correlated with the response of berry volume to plant water status. This first set of data provides information to help reasoning the adaptation of these varieties according to the expected risks of drought and the possibilities of mitigating them through irrigation.
Non-alcoholic fatty liver disease (NAFLD) is a chronic disease caused by hepatic steatosis. Adenosine deaminases acting on RNA (ADARs) catalyze adenosine to inosine RNA editing. However, the functional role of ADAR2 in NAFLD is unclear. ADAR2+/+/GluR-BR/R mice (wild type, WT) and ADAR2-/-/GluR-BR/R mice (ADAR2 KO) mice are fed with standard chow or high-fat diet (HFD) for 12 weeks. ADAR2 KO mice exhibit protection against HFD-induced glucose intolerance, insulin resistance, and dyslipidemia. Moreover, ADAR2 KO mice display reduced liver lipid droplets in concert with decreased hepatic TG content, improved hepatic insulin signaling, better pyruvate tolerance, and increased glycogen synthesis. Mechanistically, ADAR2 KO effectively mitigates excessive lipid production via AMPK/Sirt1 pathway. ADAR2 KO inhibits hepatic gluconeogenesis via the AMPK/CREB pathway and promotes glycogen synthesis by activating the AMPK/GSK3β pathway. These results provide evidence that ADAR2 KO protects against NAFLD progression through the activation of AMPK signaling pathways.
The invention relates to a drug for treating facioplegia. The drug is prepared from, by weight, 30 parts of gaultheria pyroloides, 13 parts of herb of henbit deadnettle, 10 parts of herba lycopodii, 12 parts of microsorium hymenodes, 12 parts of Japanese raspberry, 12 parts of ellpticleaf spurgentian root, 22 parts of philippine flemingia root, 20 parts of diamondleaf persimmon root or branchlet and 12 parts of leaf of velutinous cinquefoil. Gaultheria pyroloides can dispel wind and eliminate dampness and activate meridians to stop pain. Herb of henbit deadnettle can promote blood circulation to remove meridian obstruction and achieve detumescence by detoxification. Herba lycopodii can relax the muscles and stimulate the blood circulation, calm liver and remove dampness and relieve internal heat or fever. Microsorium hymenodes can clear heat and stop cough, promote blood circulation to remove meridian obstruction and remove dampness and relieve pain. Japanese raspberry can clear away heat and toxic materials, eliminate stagnant blood and stop bleeding, and kill insects to treat sores. Ellpticleaf spurgentian root can clear away heat and toxic materials, soothe liver-gallbladder and expel wind to relieve pain. Philippine flemingia root can dispel wind and remove dampness, strengthen tendons and bones, and activate blood and relieve internal heat or fever. Diamondleaf persimmon root or branchlet can clear dampness and heat, benefit liver and gall and promote blood circulation to remove blood stasis. Leaf of velutinous cinquefoil promote the circulation of qi and help to digest, achieve astringency and hemostasis, and clear heat and activate blood. Through the combination of the medicinal materials, the functions of invigorating qi and blood, dispelling wind and removing obstruction in the meridians, tranquilizing mind by nourishing the heart, removing dampness and reducing phlegm are realized. Clinical experiments prove that the drug can safely and effectively treating facioplegia.